$25.50
21.20% yesterday
Nasdaq, May 16, 10:00 pm CET
ISIN
US1717571079
Symbol
CDTX
Sector
Industry

Cidara Therapeutics, Inc. Stock price

$25.50
+6.32 32.95% 1M
+10.54 70.45% 6M
-1.38 5.13% YTD
+13.50 112.50% 1Y
+16.57 185.55% 3Y
-38.50 60.16% 5Y
-308.30 92.36% 10Y
Nasdaq, Closing price Fri, May 16 2025
+4.46 21.20%
ISIN
US1717571079
Symbol
CDTX
Sector
Industry

Key metrics

Market capitalization $330.73m
Enterprise Value $158.91m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 529.70
P/S ratio (TTM) P/S ratio 1,102.43
P/B ratio (TTM) P/B ratio 2.20
Revenue growth (TTM) Revenue growth -99.35%
Revenue (TTM) Revenue $300.00k
EBIT (operating result TTM) EBIT $-113.46m
Free Cash Flow (TTM) Free Cash Flow $-191.95m
Cash position $174.49m
EPS (TTM) EPS $-29.07
P/E forward negative
Short interest 3.61%
Show more

Is Cidara Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

Cidara Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Cidara Therapeutics, Inc. forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Cidara Therapeutics, Inc. forecast:

Buy
100%

Financial data from Cidara Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.30 0.30
99% 99%
100%
- Direct Costs 0.23 0.23
94% 94%
77%
0.08 0.08
100% 100%
27%
- Selling and Administrative Expenses 23 23
22% 22%
7,583%
- Research and Development Expense 91 91
47% 47%
30,187%
-113 -113
203% 203%
-37,743%
- Depreciation and Amortization 0.23 0.23
71% 71%
77%
EBIT (Operating Income) EBIT -113 -113
197% 197%
-37,819%
Net Profit -181 -181
397% 397%
-60,393%

In millions USD.

Don't miss a Thing! We will send you all news about Cidara Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cidara Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
2 days ago
SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that it will host a virtual research and development (R&D) day on Thursday, May 22, 2025, from 10:00 to 11:30 AM ET. To register, click here.
Neutral
GlobeNewsWire
4 days ago
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below investor conferences. Event: RBC Global Healthcare Conference Date: Wednesday, May 21, 2025 Time: 10:00 AM ET Event: Jefferie...
Neutral
Seeking Alpha
7 days ago
Cidara Therapeutics, Inc. (NASDAQ:CDTX ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Brian Ritchie - LifeSci Advisors Jeffrey Stein - President and Chief Executive Officer Frank Karbe - Chief Financial Officer Nicole Davarpanah - Chief Medical Officer Les Tari - Chief Scientific Officer Jim Beitel - Chief Business Officer Conference Call Participants Eric Schmid...
More Cidara Therapeutics, Inc. News

Company Profile

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Head office United States
CEO Jeffrey Stein
Employees 38
Founded 2012
Website www.cidara.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today